ASH: Focus on Lymphoma
Advertisement
Advertisement
Progression-free survival was significantly prolonged with the combination compared with a placebo.
The results were presented at the 65th American Society of Hematology Annual Meeting & Exposition in San Diego.
The data came from ZUMA-2, a phase II, open-label, multicenter, single-arm trial in which participants received brexu-cel.
The abstract investigators presented data from the phase II TRANSCEND FL trial.
Pirtobrutinib showed potential efficacy among patients with relapsed or refractory follicular lymphoma.
Polatuzumab-based bridging was associated with high overall response rate and complete response rate.
The SEER database was used to examine disparities in incidence and survival outcomes between different races.
Liso-cel "should continue to be a really good option for these older patients," Dr. Sehgal said.
Adults older than 65 and newly diagnosed with DLBCL or DLBCL/high-grade BCL with MYC and BCL2 rearrangements were surveyed.
Researchers examined registry data for patients with previously untreated DLBCL or high-grade BCL treated with R-CHOP.
Those high-risk disease features include high proliferation index, TP53 mutation, blastoid morphology, and CNS lymphoma.
One-time liso-cel infusion demonstrated durable responses in R/R LBCL.
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines and may function as a powerful prognostic indicator.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.